Form 4 for AKTX Akari Therapeutics Plc
Accepted 2024-04-30 00:00:00 ET · period of report 2024-04-26 · accession 0000950170-24-050854 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-30 | 2024-04-26 | AKTX | Jacques Rachelle Suzanne | CEO, Dir | A - Grant | $0.00 | +479.57M | 1.02B | +89% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares, par value $0.0001 per share | 2024-04-26 | A | A | 479,569,892 | $0.00 | 1,018,027,792 | D | — | — | (F1) These shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive one ordinary share, par value $0.0001. 50% of the RSUs shall vest on March 28, 2025, with the remainder vesting in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |